

Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief, *Neurology*[®]




Notable in *Neurology* this week

This issue features an article that compares cost-effectiveness of different genetic testing strategies in patients with epilepsy; another evaluates sociodemographic, socioeconomic, and clinical risk factors for possible REM sleep behavior disorder in a national cohort. A featured Views & Reviews assesses the implications of language, specifically in the continued use of “cerebral palsy” rather than transitioning to “cerebral palsy spectrum disorder.”

Articles

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study



Investigating the association between longitudinal changes in proton magnetic resonance spectroscopy metabolites and amyloid pathology, the authors demonstrate that longitudinal changes in myo-inositol/creatine and N-acetylaspartate/myo-inositol are associated with underlying amyloid pathology. Depending on amyloid β 42 status, magnetic resonance spectroscopy metabolites may predict the rate of future cognitive decline.

Page 217

From editorialists Kantarci & Jicha: “These data provide valuable insights into ^1H MRS metabolite trajectories throughout the early course of predementia AD, without overstating their potential biological importance. This tack represents a refreshing approach in the area of novel biomarker discovery in AD.”

Page 209

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders

The authors studied anxiety, depression, and cognition in persons with multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis, and persons without these diseases. Anxiety and depression were associated with similar patterns of lower cognitive functioning in all cohorts. Managing psychiatric symptoms in multiple sclerosis and other immune-mediated diseases may mitigate adverse cognitive effects.

Page 218

From editorialists Feinstein et al.: “The need for replication should not, however, detract from the importance of these findings. They come as a wake-up call to address anxiety with the same attention currently paid to depression.”

Page 211

The neuronal network of laughing in young patients with untreated narcolepsy

This article investigates neuronal correlates of laughter in pediatric patients with narcolepsy type 1. The authors observed that the zona incerta (ZI) is highly engaged during functional MRI

Continued

MORE ONLINE

🎧 Editor's Summary

Audio summary of highlighted articles.

[NPub.org/edsum](https://www.neurology.org/edsum)

runs with laughter in patients with narcolepsy type 1, but not cataplexy. These findings support the ZI as a potential target in cataplexy treatment.

Page 226

Special Article

Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement

The accurate and timely determination of brain death is an integral component of American Academy of Neurology members' professional responsibility to their patients. This position statement provides guidance to physicians who encounter resistance to brain death or requests for accommodation including continued use of organ support technology despite neurologic determination of death.

Page 228

NB: "Eccentric target sign in CNS toxoplasmosis: A rare presentation of Good syndrome," p. e516. To check out other Resident & Fellow Mystery Cases, point your browser to Neurology.org/N and click on the link to the Resident & Fellow Section. At the end of the issue, check out the Clinical/Scientific Note discussing the diagnostic and clinical challenges of neurosarcoidosis, specifically in a case that presented within a patient's spinal cord. This week also includes a Patient Page titled "Genetic testing: Do doctors have it backward?"

NEW EPISODE



January 29, 2019

🎧 CME Opportunity:

Listen to this week's *Neurology* Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement (see p. 228)

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement
2. What's Trending: On tau protein and Alzheimer dementia symptoms

In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.

Disclosures can be found at Neurology.org.

Neurology®

Spotlight on the January 29 issue

Robert A. Gross

Neurology 2019;92;207-208

DOI 10.1212/WNL.0000000000006841

This information is current as of January 28, 2019

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/92/5/207.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

